Abrocitinib Effective Against Moderate-to-Severe Atopic Dermatitis: Study Jacinthlyn Sylvia23 Feb 2025 9:45 PM ISTA new study from Huashan Hospital, Shanghai, provided strong evidence supporting the efficacy and safety of abrocitinib for treating...
Pfizer Gets CDSCO Panel nod to Import Abrocitinib tablets for moderate to severe atopic dermatitis Dr. Divya Colin26 Dec 2024 6:00 PM ISTNew Delhi: Pharmaceutical major Pfizer Products India has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Conduct Active Surveillance Study: CDSCO Panel Tells Pfizer on Abrocitinib tablets Dr. Divya Colin26 Sept 2024 6:00 PM ISTNew Delhi: In line with the drug major Pfizer Products proposal to waive the specific condition mentioned in the import and marketing permission of...
Abrocitinib therapy effective in patients with Atopic dermatitis: Study Jacinthlyn Sylvia8 July 2024 5:15 AM ISTA new study published in the International Journal of Dermatology suggests that abrocitinib is an effective therapy for atopic dermatitis (AD) since...
Abrocitinib monotherapy effective and well tolerated in adults with prurigo nodularis or chronic pruritus: Study Dr. Shravani Dali22 Jun 2024 6:30 AM ISTAbrocitinib monotherapy is effective and well tolerated in adults with prurigo nodularis or chronic pruritus of unknown origin suggests a study...
Drug used to treat eczema may provide relief for patients with intensely itchy skin diseases: JAMA Dr. Kamal Kant Kohli7 Jun 2024 8:00 PM ISTA drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no...
Long-term treatment with abrocitinib safe and effective for patients with moderate-to-severe atopic dermatitis Dr. Kamal Kant Kohli7 Aug 2023 10:15 AM ISTGermany: Findings from the long-term extension JADE EXTEND study supported Abrocitinib as an effective treatment for patients with moderate-to-severe...
Abrocitinib effective treatment option for lichen sclerosus Medha Baranwal25 May 2023 9:15 AM ISTChina: Abrocitinib may provide disease control in Lichen sclerosus (LS) patients; however, more extensive controlled trials are required for results...
USFDA approves Pfizer CIBINQO for adolscents with refractory atopic dermatitis Ruchika Sharma12 Feb 2023 1:00 PM ISTCIBINQO is an oral inhibitor of Janus kinase (JAK) 1.
Abrocitinib bests dupilumab for treating moderate-to-severe atopic dermatitis: Lancet Dr. Shravani Dali18 Aug 2022 11:15 AM ISTAbrocitinib 200 mg per day is more efficacious than dupilumab in adults with moderate-to-severe atopic dermatitis according to a recent study...
Pfizer Cibinqo gets USFDA nod to treat Atopic Dermatitis Ruchika Sharma15 Jan 2022 12:00 PM ISTNew York: Pfizer Inc. has announced that the United States (U.S.) Food and Drug Administration (FDA) has approved CIBINQO (abrocitinib), an oral,...
Pfizer Abrocitinib for atopic dermatitis approved in Japan Ruchika Sharma3 Oct 2021 9:00 AM ISTNew York: Pfizer Inc. has recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved...
